- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 09.12.25 | Insider Selling: GUY NOHRA Unloads $75K Of Bioventus Stock | 2 | Benzinga.com | ||
| 17.11.25 | Bioventus beruft Ajay Dhankhar in den Verwaltungsrat | 2 | Investing.com Deutsch | ||
| 17.11.25 | Bioventus Inc. - 8-K, Current Report | - | SEC Filings | ||
| 04.11.25 | Bioventus surges on Q3 beats | 2 | Seeking Alpha | ||
| 04.11.25 | Bioventus Shares Jump 19% Following Positive Q3 Results | 2 | RTTNews | ||
| 04.11.25 | Bioventus Q3 2025 slides: 8% organic growth with margins expanding despite flat revenue | 2 | Investing.com | ||
| 04.11.25 | Bioventus übertrifft Q3-Erwartungen dank 8 % organischem Umsatzwachstum | - | Investing.com Deutsch | ||
| BIOVENTUS Aktie jetzt für 0€ handeln | |||||
| 04.11.25 | Bioventus Non-GAAP EPS of $0.15 beats by $0.03, revenue of $138.7M beats by $0.51M | 1 | Seeking Alpha | ||
| 04.11.25 | Bioventus, Inc.: Bioventus Reports Third Quarter Financial Results | 483 | GlobeNewswire (Europe) | Q3 reported revenue of $138.7 million was comparable to last year and organic* revenue advanced 8%Third quarter GAAP earnings of $0.05 per diluted share increased compared to the prior-year period... ► Artikel lesen | |
| 04.11.25 | Bioventus Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 04.11.25 | Bioventus Inc. - 8-K, Current Report | - | SEC Filings | ||
| 28.10.25 | Bioventus, Inc.: Bioventus to Report Third Quarter of Fiscal Year 2025 Financial Results on November 4, 2025 | 1 | GlobeNewswire (USA) | ||
| 10.09.25 | Bioventus präsentiert Wachstumsstrategie und Turnaround-Plan auf Morgan Stanley Konferenz | 2 | Investing.com Deutsch | ||
| 30.07.25 | Bioventus, Inc.: Bioventus Receives FDA 510(k) Clearances for two Next-Generation Peripheral Nerve Stimulation Products | 345 | GlobeNewswire (Europe) | DURHAM, N.C., July 30, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, announced today a significant milestone with the U.S. Food and Drug... ► Artikel lesen | |
| 06.05.25 | Bioventus, Inc.: Bioventus Reports First Quarter Financial Results | 144 | GlobeNewswire (Europe) | Q1 reported revenue of $123.9 million declined 4.3%; Organic* revenue advanced 5.0%First quarter net loss was $0.04 per share compared to a loss of $0.08 in the prior-year periodNon-GAAP earnings*... ► Artikel lesen | |
| 11.03.25 | Bioventus, Inc.: Bioventus Announces Fourth Quarter and Full Year 2024 Financial Results | 257 | GlobeNewswire (Europe) | Accelerated fourth quarter sales growth to 13.5%Fourth quarter gross margin expanded 310 bps and adjusted gross margin* expanded 230 bpsFourth quarter cash from operations of $19.3 million increased... ► Artikel lesen |
16 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 42,885 | -1,36 % | Diagnostikkonzern Qiagen überrascht im Schlussquartal - Weiteres Wachstum 2026 | VENLO/HILDEN (dpa-AFX) - Qiagen hat 2025 von einer anziehenden Nachfrage nach seinen Kernprodukten profitiert. Dabei lief das Schlussquartal besser als vom Labordienstleister und Diagnostikkonzern... ► Artikel lesen | |
| LIMINATUS PHARMA | 1,550 | -15,76 % | Liminatus Pharma, Inc. - 8-K, Current Report | ||
| STRUCTURE THERAPEUTICS | 77,80 | +3,79 % | Structure Therapeutics Inc.: Structure Therapeutics Announces Initiation of Phase 1 Clinical Study of Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity | SAN FRANCISCO, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 3,935 | -0,63 % | Recursion Pharmaceuticals, Inc.: Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks | REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden and a 43% median reduction after 12 weeks of treatment (n=12)After 12 weeks... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 72,89 | -0,02 % | Avidity Biosciences, Inc. - 8-K, Current Report | ||
| PRAXIS PRECISION MEDICINES | 319,00 | -0,18 % | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| BIONTECH | 91,25 | +1,11 % | Startschuss! BioTech-Sektor profitiert von Rotation! Augen auf bei Evotec, Bayer, Vidac Pharma and BioNTech | Mit positiver Grundstimmung hat die Börse das Jahr 2026 eingeläutet. Dass Renditechancen nicht allein im Technologiesektor liegen, bewies zuletzt der Minen- und Rohstoffbereich, wo etliche Titel Kursverdopplungen... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 62,39 | +0,32 % | Jefferies lowers Apogee Therapeutics stock price target on OX40 concerns | ||
| COGENT BIOSCIENCES | 37,660 | +1,67 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Breakthrough Therapy Designation for Bezuclastinib in Combination with Sunitinib for Patients with Gastrointestinal Stromal Tumors (GIST) | - Cogent will submit the PEAK New Drug Application (NDA) under previously announced RTOR designation; on track to complete NDA submission in April 2026 WALTHAM, Mass. and BOULDER, Colo., Jan. 26... ► Artikel lesen | |
| IMMUNOVANT | 27,360 | +1,18 % | Immunovant Inc.: Immunovant Provides Corporate Updates and Reports Financial Results for the Third Quarter Ended December 31, 2025 | IMVT-1402 potentially registrational trial in difficult-to-treat rheumatoid arthritis (D2T RA) fully enrolled, with topline data expected in the second half of calendar year 2026; topline data from... ► Artikel lesen | |
| ERASCA | 12,130 | -1,30 % | Stifel bestätigt Kaufempfehlung für Erasca mit Kursziel von 10 US-Dollar | ||
| CG ONCOLOGY | 49,650 | -1,35 % | CG Oncology Inc.: CG Oncology Provides Updated Timeline for PIVOT-006 Phase 3 Topline Data in Intermediate-Risk NMIBC | - PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy for intermediate-risk NMIBC now expected in 1H 2026, nearly one year ahead of schedule - First randomized registrational trial... ► Artikel lesen | |
| TANGO THERAPEUTICS | 12,860 | +2,63 % | Expert Outlook: Tango Therapeutics Through The Eyes Of 4 Analysts | ||
| PRENETICS GLOBAL | 21,010 | +18,63 % | Prenetics Global Limited: Prenetics Announces Update to Capital Allocation Strategy; Ceases Bitcoin Purchases to Focus on IM8 | Company's Capital and Strategic Focus Now Exclusively Focused on IM8 IM8 FY 2026 Revenue Projected to Reach $180 - $200 Million CHARLOTTE, N.C., Dec. 30, 2025 (GLOBE NEWSWIRE) -- Prenetics Global... ► Artikel lesen | |
| BEAM THERAPEUTICS | 26,850 | +1,28 % | Beam Therapeutics Inc. - 8-K, Current Report |
BIOVENTUS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 8,560 Euro und damit +0,47 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIOVENTUS INC finden Sie auf Wallstreet Online.